AFM
CRDF icon

Anson Funds Management’s Cardiff Oncology CRDF Stock Holding History

Anson Funds Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-69,381
Closed -$417K – 364
2021
Q4 		$417K Buy
+69,381
New +$414K 0.04% 258

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Anson Funds Management's CRDF Position: Q1 2022 in Review

Anson Funds Management sold out of Cardiff Oncology (CRDF) in Q1 2022, closing a stake of 69,381 shares — an estimated $417K sold.

Anson Funds Management first reported a position in CRDF in Q4 2021 and held it in 1 quarter. The position peaked at $417K in Q4 2021. 91 funds tracked by Wall St. Rank hold CRDF as of Q1 2022.

  • Anson Funds Management reported no remaining Cardiff Oncology position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 69,381 Cardiff Oncology shares in Q1 2022, an estimated $417K.
  • Anson Funds Management first reported a position in Cardiff Oncology in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Cardiff Oncology position peaked at $417K in Q4 2021.
  • 91 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.